VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Vertex Pharmaceuticals is in the process of ... like it's on the verge of bearing fruit once again. On Oct. 20, the company presented new information about its non-opioid oral analgesic candidate ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

The adjustment reflects Vertex's strong performance in its cystic fibrosis (CF) business, which has outperformed expectations. The company's recent financial results have demonstrated the ...

Several other equities analysts have also issued reports on the company. Jefferies Financial Group raised Vertex from a “hold” rating to a “buy” rating and raised their price objective for ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, released new innovations, honored partners and ...

It’s been a busy few years for 32-year-old Oliver Smith. After leaving school, he honed his carpentry skills before moving to ...